The impact and prognostic significance of chronic lymphocytic leukemia upregulated 1 (cllu1) gene expression in patients with chronic lymphocytic leukemia: A single center experience
Lab Medicine, cilt.51, sa.3, ss.259-264, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 51 Sayı: 3
- Basım Tarihi: 2020
- Doi Numarası: 10.1093/labmed/lmz058
- Dergi Adı: Lab Medicine
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.259-264
- Anahtar Kelimeler: chronic lymphocytic leukemia, chronic lymphocytic leukemia upregulated 1 gene, CLLU1, ZAP-70, prognosis, beta(2)-microglobulin
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: To determine CLLU1 gene levels and the relationship of that gene among other prognostic parameters in patients with chronic lymphocytic leukemia. Methods: Bone-marrow infiltration pattern, β2-microglobulin (β 2-M), cluster of differentiation (CD)38, and ZAP-70 status were recorded. CLLU1 levels were assessed by real-time polymerase chain reaction (RT-PCR) and expressed as folds. The relationship between CLLU1 and other known prognostic parameters was evaluated. Results: CLLU1 expression was positive in 81 patients and negative in 3 patients. The median (interquartile range [IQR]) CLLU1 level was 6.45 folds (3.75-16.57 folds) in patients with β 2-M normal values and 16.22 folds (3.91-62.00 folds) in patients with increased β 2-M (P = .15). Patients with a higher CD38 value than the median level had 3 times higher CLLU1 levels than the other group (P = .07). The median (IQR) CLLU1 level was 4.25 folds (2.75-13.71 folds) in patients with CLL who tested negative on ZAP-70, whereas it was 49.52 folds (15.06- 446.36 folds) in those who tested positive via ZAP-70 (P = .005). Conclusions: CLLU1 is a specific parameter to CLL, and its level corresponds well with the ZAP-70 level.